https://cohostpodcasting.com <![CDATA[Invent: Life Sciences]]> en 640487af-a806-489d-b996-f8b6fd7191d1 Wed, 12 Jun 2024 17:42:07 -0400 Wed, 18 Mar 2026 09:29:47 -0400 https://ttp.com/invent <![CDATA[Invent: Life Sciences]]> https://files.cohostpodcasting.com/quill-file-prod/3db9f9c9-a22f-469a-838e-a5cb6f604796/shows/640487af-a806-489d-b996-f8b6fd7191d1/cover-art/original_7d4266893339f6635952b74e465c9e00.jpg https://ttp.com/invent episodic false https://feeds.cohostpodcasting.com/ExCa0DXE Adam.Roberts@ttp.com 2aca7fb0-3a3d-42f2-adbb-748b79259301 <![CDATA[Lessons from Season 3]]> In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes to move from discovery to delivery.


Featuring insights from leaders across Novartis, Cellular Origins, Orchard Therapeutics, Charles River, Cytiva, OmniaBio, Eli Lilly, and more,  this season revealed how the biotech industry must evolve to make breakthrough therapies accessible, affordable, and ready for global deployment.


]]> Mon, 20 Oct 2025 00:00:00 -0400 https://ttp.com/invent 2:29 In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes to move from discovery to delivery.


Featuring insights from leaders across Novartis, Cellular Origins, Orchard Therapeutics, Charles River, Cytiva, OmniaBio, Eli Lilly, and more,  this season revealed how the biotech industry must evolve to make breakthrough therapies accessible, affordable, and ready for global deployment.


]]> In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes to move from discovery to delivery.


Featuring insights from leaders across Novartis, Cellular Origins, Orchard Therapeutics, Charles River, Cytiva, OmniaBio, Eli Lilly, and more,  this season revealed how the biotech industry must evolve to make breakthrough therapies accessible, affordable, and ready for global deployment.


]]> false full 7 3 f5fbf250-e296-42da-852a-bc7095aa9fd5 <![CDATA[ Make Way for Advanced Therapies – Why Manufacturing Could be Coming to a Hospital Near You]]> In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.


Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.


Guests:


  • Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
  • Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust


]]> Mon, 22 Sep 2025 00:00:00 -0400 https://ttp.com/invent 38:05 In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.


Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.


Guests:


  • Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
  • Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust


]]> In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.


Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.


Guests:


  • Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
  • Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust


]]> false full 6 3 ced17d05-bcda-4a6f-a657-56e395a8cac3 <![CDATA[Automation, Access, and the Future of Manufacturing]]> Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.


Guests:


]]> Mon, 15 Sep 2025 00:00:00 -0400 https://ttp.com/invent 37:25 Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.


Guests:


]]> Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.


Guests:


]]> false full 5 3 ec3f920e-b3bd-419a-b321-72718038b97c <![CDATA[Scaling Cell & Gene Therapies: From Breakthroughs to the Mass Market]]> In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts as they discuss what must change for CGTs to deliver on their full potential.


]]> Thu, 11 Sep 2025 00:00:00 -0400 https://ttp.com/invent 3:32 In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts as they discuss what must change for CGTs to deliver on their full potential.


]]> In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts as they discuss what must change for CGTs to deliver on their full potential.


]]> false trailer 3 e9c897a5-0888-46e3-8d45-e4f73cec3b5a <![CDATA[From Promise to Practice – AI's Impact on Cell and Gene Therapy Development]]> In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Global Institute estimates that generative AI could generate up to $100 billion in economic value for pharma and medical product companies, and therapy developers are eager to see these benefits sooner rather than later, no more so than in the complex and challenging field of cell and gene therapies. With the help of two expert guests, Stuart will uncover how AI is being used in the industry today, and where it could go in the future. 


Guests:



]]> Mon, 27 Jan 2025 00:00:00 -0500 https://ttp.com/invent 34:36 In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Global Institute estimates that generative AI could generate up to $100 billion in economic value for pharma and medical product companies, and therapy developers are eager to see these benefits sooner rather than later, no more so than in the complex and challenging field of cell and gene therapies. With the help of two expert guests, Stuart will uncover how AI is being used in the industry today, and where it could go in the future. 


Guests:



]]> In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Global Institute estimates that generative AI could generate up to $100 billion in economic value for pharma and medical product companies, and therapy developers are eager to see these benefits sooner rather than later, no more so than in the complex and challenging field of cell and gene therapies. With the help of two expert guests, Stuart will uncover how AI is being used in the industry today, and where it could go in the future. 


Guests:



]]> false full 4 3 b72f310e-4a18-415d-9021-5cf5c29a38e9 <![CDATA[From Plastics to Partnerships - The Path to Sustainability in Biopharma]]> In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva, and Wenshu Xu, Drug Discovery Tools Team Lead at TTP, we review the progress made by the industry so far and some examples where innovative thinking has had an impact on operations. Topics include the challenge of tackling Scope 3 emissions, reducing the impact of single-use plastics, and how collaboration across the ecosystem is key to meeting ambitious sustainability targets.

Guests:


]]> Mon, 13 Jan 2025 00:00:00 -0500 https://ttp.com/invent 40:05 In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva, and Wenshu Xu, Drug Discovery Tools Team Lead at TTP, we review the progress made by the industry so far and some examples where innovative thinking has had an impact on operations. Topics include the challenge of tackling Scope 3 emissions, reducing the impact of single-use plastics, and how collaboration across the ecosystem is key to meeting ambitious sustainability targets.

Guests:


]]> In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva, and Wenshu Xu, Drug Discovery Tools Team Lead at TTP, we review the progress made by the industry so far and some examples where innovative thinking has had an impact on operations. Topics include the challenge of tackling Scope 3 emissions, reducing the impact of single-use plastics, and how collaboration across the ecosystem is key to meeting ambitious sustainability targets.

Guests:


]]> false full 3 3 1c1782ee-a8b2-4c2f-9cb8-18ac66945495 <![CDATA[How Climate Change and AI are Driving Innovation in Biopharma]]> In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industry faces mounting pressure to address its carbon emissions, deploy cutting-edge digital technology, while streamlining operations. Along with his guests, discover the innovative approaches that are being taken to transform drug development and manufacturing.

]]> Mon, 06 Jan 2025 12:40:00 -0500 https://ttp.com/invent 2:49 In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industry faces mounting pressure to address its carbon emissions, deploy cutting-edge digital technology, while streamlining operations. Along with his guests, discover the innovative approaches that are being taken to transform drug development and manufacturing.

]]> In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industry faces mounting pressure to address its carbon emissions, deploy cutting-edge digital technology, while streamlining operations. Along with his guests, discover the innovative approaches that are being taken to transform drug development and manufacturing.

]]> false trailer 3 e7417105-da1b-4c39-abd2-28eee169d215 <![CDATA[How Innovation Can Broaden Access and Propel the CGT Industry Forward]]> In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.


Guests:

  • Emma Chan, Director of Technical Development at Orchard Therapeutics
  • Matt Hewitt, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories


]]> Mon, 23 Sep 2024 00:00:00 -0400 https://ttp.com/invent 47:26 In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.


Guests:

  • Emma Chan, Director of Technical Development at Orchard Therapeutics
  • Matt Hewitt, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories


]]> In Part One of this two-part series, we reflected on the progress made in the Cell and Gene Therapy (CGT) industry and the importance of patient-centric development. In this episode, we dive into how we can continue to move forward, broaden access, and encourage the development of new treatments. We’ll discuss the critical need to scale manufacturing, even in the early stages of development, to ensure that these therapies reach the patients who need them.


Guests:

  • Emma Chan, Director of Technical Development at Orchard Therapeutics
  • Matt Hewitt, Chief Technical Officer at the Manufacturing Business Division at Charles River Laboratories


]]> false full 2 3 89213473-250b-476d-8075-3b1f4cbc20e6 <![CDATA[Why Do We Need to Continue Innovating in the CGT Industry?]]> The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?

Guests:

  • Tay Salimullah, Chief Access Commercial Officer at Novartis
  • Jason Jones, Global Business Development Lead at Cellular Origins


]]> Mon, 16 Sep 2024 00:00:00 -0400 https://ttp.com/invent 46:19 The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?

Guests:

  • Tay Salimullah, Chief Access Commercial Officer at Novartis
  • Jason Jones, Global Business Development Lead at Cellular Origins


]]> The Cell and Gene Therapy (CGT) industry has made remarkable strides, with significant advancements and the approval of groundbreaking technologies in recent years. However, have we become too dependent on older methods, and are we doing enough to ensure these new therapies are reaching as many patients as possible? In this episode, we tackle these questions while exploring one fundamental issue: Why? Why is it essential to continue innovating to broaden patient access, develop new therapies, and push the industry forward?

Guests:

  • Tay Salimullah, Chief Access Commercial Officer at Novartis
  • Jason Jones, Global Business Development Lead at Cellular Origins


]]> false full 1 3 a3db0264-c203-40a8-ae7d-ba3c264e1e42 <![CDATA[Welcome Back to Invent: Life Sciences - Season 3 Trailer]]> Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this series, we’ll be looking at the people, processes and partnerships we’ll need to continue moving forwards and delivering the best outcomes for the greatest number of patients.


Over the forthcoming two episodes, I’ll be joined by 4 expert guests to answer two fundamental questions: why do we need to continue to innovate, and how can we do it.

]]> Mon, 09 Sep 2024 00:00:00 -0400 https://ttp.com/invent 1:48 Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this series, we’ll be looking at the people, processes and partnerships we’ll need to continue moving forwards and delivering the best outcomes for the greatest number of patients.


Over the forthcoming two episodes, I’ll be joined by 4 expert guests to answer two fundamental questions: why do we need to continue to innovate, and how can we do it.

]]> Welcome back to Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


With approvals for advanced therapies on the rise, and aspirations to target larger patient populations, it’s time to take stock and reflect and on the progress made to date. In this series, we’ll be looking at the people, processes and partnerships we’ll need to continue moving forwards and delivering the best outcomes for the greatest number of patients.


Over the forthcoming two episodes, I’ll be joined by 4 expert guests to answer two fundamental questions: why do we need to continue to innovate, and how can we do it.

]]> false trailer 0 3 34950527-46c8-48e8-9cba-76328d3b4744 <![CDATA[The Highlights: A look back at the best moments of Invent: Life Sciences Series 2]]> Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. 

We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research. 

A big thank you to all our guests that featured in this series, make sure you show your appreciation to our esteemed guests by re-listening to your favorite episode and subscribing to Invent: Life Sciences from wherever you get your podcasts. 

And finally, a big thank you to you, our listeners, for tuning in each week throughout this series. What has been your favorite episode? Get in touch and let us know!


So for the last time in this series... join me, Stuart Lowe, as we dive into the best bits of Invent: Life Sciences Series 2, a podcast brought to you by technology and product development company TTP.

]]> Wed, 15 Nov 2023 15:19:24 -0500 https://ttp.com/invent 14:07 Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. 

We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research. 

A big thank you to all our guests that featured in this series, make sure you show your appreciation to our esteemed guests by re-listening to your favorite episode and subscribing to Invent: Life Sciences from wherever you get your podcasts. 

And finally, a big thank you to you, our listeners, for tuning in each week throughout this series. What has been your favorite episode? Get in touch and let us know!


So for the last time in this series... join me, Stuart Lowe, as we dive into the best bits of Invent: Life Sciences Series 2, a podcast brought to you by technology and product development company TTP.

]]> Throughout this series of Invent, we have brought you cutting-edge developments in the Life Sciences industry. 

We have spoken to a wide range of guests who have provided fascinating insights into the manufacture of cell and gene therapies, and what developments in drug testing mean for the future of genetic research. 

A big thank you to all our guests that featured in this series, make sure you show your appreciation to our esteemed guests by re-listening to your favorite episode and subscribing to Invent: Life Sciences from wherever you get your podcasts. 

And finally, a big thank you to you, our listeners, for tuning in each week throughout this series. What has been your favorite episode? Get in touch and let us know!


So for the last time in this series... join me, Stuart Lowe, as we dive into the best bits of Invent: Life Sciences Series 2, a podcast brought to you by technology and product development company TTP.

]]> false full 9 2 6b1c44b0-1683-4c43-b0dc-8b98e4f95a8e <![CDATA[Process Analytics: how can analytics accelerate the development and manufacture of cell and gene therapies?]]> Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide the insights therapy developers need? And how can new technologies be implemented in the fast-moving life sciences field?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Davide Danovi
Davide Danovi leads the cellular pheotyping department at bit.bio. Bit.bio is an award-winning human synthetic biology enterprise with a mission to code cells for health through applying the principles of computation to biology. In his role at bit.bio, Davide's responsibilities emcompass three key areas. Firstly, Infrastructure and training, overseeing the maintenance of essential instruments, conducts staff training, and establishes data analysis infrastructure for imaging and flow cytometry. Secondly, Cell characterisation, verifying the identities of cells, ensuring the accuracy and reliability of experimental results. And finally, Cell type identification, developing modules to precisely identify specific cell types by screening transcription factors, offering innovative solutions for cell identification.

James Kusena
James Kusena is the Vice President of Operations at MicrofluidX. MicrofluidX is industrialising cell and gene therapy manufacturing through it's latest technology, the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing. James' career began with a focus on bioprocessing and applications, now as VP of Operations, this focus is now shaping the company's technology to align with industry needs. With demonstrated experience in various sectors of the Cell and Gene therapy industry, including: Process Development, Process Translation, Process Transfer, Research & Development and Commercialisation; James' career reflects a fusion of technical expertise and leadership with a commitment to advancing cell therapy manufacturing industry standards and product quality.

]]> Tue, 07 Nov 2023 18:42:14 -0500 https://ttp.com/invent 39:42 Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide the insights therapy developers need? And how can new technologies be implemented in the fast-moving life sciences field?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Davide Danovi
Davide Danovi leads the cellular pheotyping department at bit.bio. Bit.bio is an award-winning human synthetic biology enterprise with a mission to code cells for health through applying the principles of computation to biology. In his role at bit.bio, Davide's responsibilities emcompass three key areas. Firstly, Infrastructure and training, overseeing the maintenance of essential instruments, conducts staff training, and establishes data analysis infrastructure for imaging and flow cytometry. Secondly, Cell characterisation, verifying the identities of cells, ensuring the accuracy and reliability of experimental results. And finally, Cell type identification, developing modules to precisely identify specific cell types by screening transcription factors, offering innovative solutions for cell identification.

James Kusena
James Kusena is the Vice President of Operations at MicrofluidX. MicrofluidX is industrialising cell and gene therapy manufacturing through it's latest technology, the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing. James' career began with a focus on bioprocessing and applications, now as VP of Operations, this focus is now shaping the company's technology to align with industry needs. With demonstrated experience in various sectors of the Cell and Gene therapy industry, including: Process Development, Process Translation, Process Transfer, Research & Development and Commercialisation; James' career reflects a fusion of technical expertise and leadership with a commitment to advancing cell therapy manufacturing industry standards and product quality.

]]> Throughout this series, we’ve explored different diseases we target, the sorts of cells which are under development as therapies, and how the therapies themselves are manufactured. With all this innovation, we shouldn’t be surprised by the increased focus on the means by which processes and products themselves are characterised. So, do current process analytical tools provide the insights therapy developers need? And how can new technologies be implemented in the fast-moving life sciences field?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Davide Danovi
Davide Danovi leads the cellular pheotyping department at bit.bio. Bit.bio is an award-winning human synthetic biology enterprise with a mission to code cells for health through applying the principles of computation to biology. In his role at bit.bio, Davide's responsibilities emcompass three key areas. Firstly, Infrastructure and training, overseeing the maintenance of essential instruments, conducts staff training, and establishes data analysis infrastructure for imaging and flow cytometry. Secondly, Cell characterisation, verifying the identities of cells, ensuring the accuracy and reliability of experimental results. And finally, Cell type identification, developing modules to precisely identify specific cell types by screening transcription factors, offering innovative solutions for cell identification.

James Kusena
James Kusena is the Vice President of Operations at MicrofluidX. MicrofluidX is industrialising cell and gene therapy manufacturing through it's latest technology, the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing. James' career began with a focus on bioprocessing and applications, now as VP of Operations, this focus is now shaping the company's technology to align with industry needs. With demonstrated experience in various sectors of the Cell and Gene therapy industry, including: Process Development, Process Translation, Process Transfer, Research & Development and Commercialisation; James' career reflects a fusion of technical expertise and leadership with a commitment to advancing cell therapy manufacturing industry standards and product quality.

]]> false full 8 2 909b218e-301d-4437-bbda-939396cf14bf <![CDATA[iPSCs: how could stem cells revolutionise the manufacture of advanced therapies?]]> Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufacture. So how might therapy developers benefit from the unique abilities of stem cells? And will they live up to their expectations?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Marinna Madrid
Marinna Madrid is a co-founder at Cellino, a venture capital-backed biotech company building the next generation of cell-based tissues and therapies with a proprietary platform technology. Marinna earned her PhD and MA in Applied Physics from Harvard University, where she played a significant role in co-inventing laser-based intracellular delivery techniques. Prior to her graduate studies, she completed her BSc in Biophysics at the University of California, Los Angeles, having initially started her academic journey at Riverside Community College. In addition to receiving honors for her achievevements, including the Harvard Graduate Prize Fellowship, she also earned a spot on the Forbes 30 Under 30 list for Healthcare in 2019. 


Adil Duru
Adil Duru is a Senior Research Manager at Glycostem Therapeutics. Glycostem Therapeutics is a Dutch biotech company established in 2007 that focuses on the development of Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. Adil's main research and development interest is exploring novel NK cell and T cell based cancer immunotherapy approaches including genetically engineered NK cells and T cells.

]]> Wed, 01 Nov 2023 11:10:45 -0400 https://ttp.com/invent 38:15 Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufacture. So how might therapy developers benefit from the unique abilities of stem cells? And will they live up to their expectations?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Marinna Madrid
Marinna Madrid is a co-founder at Cellino, a venture capital-backed biotech company building the next generation of cell-based tissues and therapies with a proprietary platform technology. Marinna earned her PhD and MA in Applied Physics from Harvard University, where she played a significant role in co-inventing laser-based intracellular delivery techniques. Prior to her graduate studies, she completed her BSc in Biophysics at the University of California, Los Angeles, having initially started her academic journey at Riverside Community College. In addition to receiving honors for her achievevements, including the Harvard Graduate Prize Fellowship, she also earned a spot on the Forbes 30 Under 30 list for Healthcare in 2019. 


Adil Duru
Adil Duru is a Senior Research Manager at Glycostem Therapeutics. Glycostem Therapeutics is a Dutch biotech company established in 2007 that focuses on the development of Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. Adil's main research and development interest is exploring novel NK cell and T cell based cancer immunotherapy approaches including genetically engineered NK cells and T cells.

]]> Across the life sciences industry, there is much excitement over the potential impact of stem cells in medicine. And it is clear why; these cells, which can be differentiated into any other cell type, could rewrite the playbook in terms of sourcing cellular material for advanced therapies manufacture. So how might therapy developers benefit from the unique abilities of stem cells? And will they live up to their expectations?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Marinna Madrid
Marinna Madrid is a co-founder at Cellino, a venture capital-backed biotech company building the next generation of cell-based tissues and therapies with a proprietary platform technology. Marinna earned her PhD and MA in Applied Physics from Harvard University, where she played a significant role in co-inventing laser-based intracellular delivery techniques. Prior to her graduate studies, she completed her BSc in Biophysics at the University of California, Los Angeles, having initially started her academic journey at Riverside Community College. In addition to receiving honors for her achievevements, including the Harvard Graduate Prize Fellowship, she also earned a spot on the Forbes 30 Under 30 list for Healthcare in 2019. 


Adil Duru
Adil Duru is a Senior Research Manager at Glycostem Therapeutics. Glycostem Therapeutics is a Dutch biotech company established in 2007 that focuses on the development of Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. Adil's main research and development interest is exploring novel NK cell and T cell based cancer immunotherapy approaches including genetically engineered NK cells and T cells.

]]> false full 7 2 6e64c27d-db16-4298-8deb-b05447587b1b <![CDATA[Sex and gender in medical research: how can a focus on the individual improve health outcomes for marginalised groups?]]> Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and minorities, could the underlying assumptions in medical research be a contributing factor? If so, what is being done to solve them?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests
Diana Torgersen
Diana Torgersen is the Executive Director for External Innovation & Emerging Science at Organon. Organon is a global healthcare company with a portfolio of therapies and product's in women's health, biosimilars, and established medicines across a wide array of conditions and diseases.

Shirin Heidari
Shirin Heidari is the Founding President of GENDRO, a not-for-profit organisation with a mission to advance equity through sex and gender senstive-research across discplines by creating public awareness about the implications of lack of sex and gender considerations in research and innovation.

Deana Mohr
Deana Mohr is CEO of MUVON Therapeutics. MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. 

]]> Wed, 25 Oct 2023 14:15:07 -0400 https://ttp.com/invent 35:36 Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and minorities, could the underlying assumptions in medical research be a contributing factor? If so, what is being done to solve them?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests
Diana Torgersen
Diana Torgersen is the Executive Director for External Innovation & Emerging Science at Organon. Organon is a global healthcare company with a portfolio of therapies and product's in women's health, biosimilars, and established medicines across a wide array of conditions and diseases.

Shirin Heidari
Shirin Heidari is the Founding President of GENDRO, a not-for-profit organisation with a mission to advance equity through sex and gender senstive-research across discplines by creating public awareness about the implications of lack of sex and gender considerations in research and innovation.

Deana Mohr
Deana Mohr is CEO of MUVON Therapeutics. MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. 

]]> Throughout almost all of medical history, it was assumed that the average white male response to drug trials could be extrapolated to all potential recipients. But when we look at the poorer health outcomes for women and minorities, could the underlying assumptions in medical research be a contributing factor? If so, what is being done to solve them?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests
Diana Torgersen
Diana Torgersen is the Executive Director for External Innovation & Emerging Science at Organon. Organon is a global healthcare company with a portfolio of therapies and product's in women's health, biosimilars, and established medicines across a wide array of conditions and diseases.

Shirin Heidari
Shirin Heidari is the Founding President of GENDRO, a not-for-profit organisation with a mission to advance equity through sex and gender senstive-research across discplines by creating public awareness about the implications of lack of sex and gender considerations in research and innovation.

Deana Mohr
Deana Mohr is CEO of MUVON Therapeutics. MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. 

]]> false full 6 2 3cb7ed82-b5d0-4ead-b130-199882831f1e <![CDATA[Organoids: how are in-vitro models revolutionising drug development and testing?]]> Pharmaceutical companies undertake rigorous clinical trials in order to find out which drugs are safe. But in order to better protect the people volunteering for these tests, regulators decreed that data from studies on animals would be the primary evidence needed before approving a clinical trial in humans. Testing drugs on animals has many ethical and practical issues, and so scientists are looking towards different types of in-vitro models as a solution. But what are these models? How can they move us towards safer, better trials?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Sylvia Boj
Sylvia Boj is an accomplished scientist and the current Chief Scientific Officer (CSO) of Hub Organoid. Sylvia's journey in the world of organoids began during her postdoctoral research in the laboratory of Hans Clevers - now, at Hub Organoid, Sylvia leads the charge in harnessing the potential of organoids for the pharmaceutical industry. Her mission is to translate the remarkable capabilities of organoids into a vital preclinical platform for drug development and discovery.

Bas Trietsch
Bas Trietsch is a co-founder and Chief Technology Officer at Mimetas in the Netherlands. For the past decade, Bas has been using his expertise in drug development and microfluidics to advance "organ on a chip" technology. This technology creates tiny versions of organs and tissues on a chip, allowing scientists to see how they react to different things and is more accurate than traditional methods. 

]]> Wed, 18 Oct 2023 12:28:13 -0400 https://ttp.com/invent 34:16 Pharmaceutical companies undertake rigorous clinical trials in order to find out which drugs are safe. But in order to better protect the people volunteering for these tests, regulators decreed that data from studies on animals would be the primary evidence needed before approving a clinical trial in humans. Testing drugs on animals has many ethical and practical issues, and so scientists are looking towards different types of in-vitro models as a solution. But what are these models? How can they move us towards safer, better trials?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Sylvia Boj
Sylvia Boj is an accomplished scientist and the current Chief Scientific Officer (CSO) of Hub Organoid. Sylvia's journey in the world of organoids began during her postdoctoral research in the laboratory of Hans Clevers - now, at Hub Organoid, Sylvia leads the charge in harnessing the potential of organoids for the pharmaceutical industry. Her mission is to translate the remarkable capabilities of organoids into a vital preclinical platform for drug development and discovery.

Bas Trietsch
Bas Trietsch is a co-founder and Chief Technology Officer at Mimetas in the Netherlands. For the past decade, Bas has been using his expertise in drug development and microfluidics to advance "organ on a chip" technology. This technology creates tiny versions of organs and tissues on a chip, allowing scientists to see how they react to different things and is more accurate than traditional methods. 

]]> Pharmaceutical companies undertake rigorous clinical trials in order to find out which drugs are safe. But in order to better protect the people volunteering for these tests, regulators decreed that data from studies on animals would be the primary evidence needed before approving a clinical trial in humans. Testing drugs on animals has many ethical and practical issues, and so scientists are looking towards different types of in-vitro models as a solution. But what are these models? How can they move us towards safer, better trials?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

Sylvia Boj
Sylvia Boj is an accomplished scientist and the current Chief Scientific Officer (CSO) of Hub Organoid. Sylvia's journey in the world of organoids began during her postdoctoral research in the laboratory of Hans Clevers - now, at Hub Organoid, Sylvia leads the charge in harnessing the potential of organoids for the pharmaceutical industry. Her mission is to translate the remarkable capabilities of organoids into a vital preclinical platform for drug development and discovery.

Bas Trietsch
Bas Trietsch is a co-founder and Chief Technology Officer at Mimetas in the Netherlands. For the past decade, Bas has been using his expertise in drug development and microfluidics to advance "organ on a chip" technology. This technology creates tiny versions of organs and tissues on a chip, allowing scientists to see how they react to different things and is more accurate than traditional methods. 

]]> false full 5 2 0634af46-82d2-4117-bf76-22c76818e3b1 <![CDATA[The Blood Brain Barrier: can innovations in delivery help us unlock the brain?]]> Modern medicine has helped us develop many effective treatments for diseases found throughout the body, but we’ve yet to have the same success with the brain. The so-called 'blood brain barrier' controls the passage of molecules out of the blood and into the brain, and so it’s not as easy to use the bloodstream to carry therapeutic molecules as we might do for other diseases. Could the blood brain barrier be the key to treating neurological disorders? How can we target this structure to make therapies more effective?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

James Choi
James Choi is the Principal Investigator of Non-invasive Surgery and Biopsy Laboratory at Imperial College London and is an Associate Professor in the Department of Bioengineering at the institute. The purpose of the Noninvasive Surgery & Biopsy Laboratory is to build incision-less microsurgical devices and methods to locally deliver drugs to the brain. James Choi is a leading expert on the blood brain barrier and has authored numerous research publications in the fields of noninvasive surgery and delivery through the blood brain barrier using focused ultrasound. James Choi's work at the laboratory is currently focused on treating several dieseases, including Alzheimers, using non-invasive devices for delivering drugs across the blood-brain barrier.

Sam Barker
Sam Barker is the Chief Business Officer at Somaserve, a genetic medicines company that is pioneering new medicines for crossing the blood brain barrier and other biologicial barries. Using a proprietary targeted polymer nanoparticle technology, PolyNaut®, Somaserve is delivering genetic materials to cells and tissues of choice, including targeted delivery to the central nervous system. Sam Barker has deep experience in start-up and growth stage companies across drug development from discovery to delivery, with expertise in developing and commercialising innovative platform technologies.

]]> Wed, 11 Oct 2023 04:00:00 -0400 https://ttp.com/invent 38:05 Modern medicine has helped us develop many effective treatments for diseases found throughout the body, but we’ve yet to have the same success with the brain. The so-called 'blood brain barrier' controls the passage of molecules out of the blood and into the brain, and so it’s not as easy to use the bloodstream to carry therapeutic molecules as we might do for other diseases. Could the blood brain barrier be the key to treating neurological disorders? How can we target this structure to make therapies more effective?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

James Choi
James Choi is the Principal Investigator of Non-invasive Surgery and Biopsy Laboratory at Imperial College London and is an Associate Professor in the Department of Bioengineering at the institute. The purpose of the Noninvasive Surgery & Biopsy Laboratory is to build incision-less microsurgical devices and methods to locally deliver drugs to the brain. James Choi is a leading expert on the blood brain barrier and has authored numerous research publications in the fields of noninvasive surgery and delivery through the blood brain barrier using focused ultrasound. James Choi's work at the laboratory is currently focused on treating several dieseases, including Alzheimers, using non-invasive devices for delivering drugs across the blood-brain barrier.

Sam Barker
Sam Barker is the Chief Business Officer at Somaserve, a genetic medicines company that is pioneering new medicines for crossing the blood brain barrier and other biologicial barries. Using a proprietary targeted polymer nanoparticle technology, PolyNaut®, Somaserve is delivering genetic materials to cells and tissues of choice, including targeted delivery to the central nervous system. Sam Barker has deep experience in start-up and growth stage companies across drug development from discovery to delivery, with expertise in developing and commercialising innovative platform technologies.

]]> Modern medicine has helped us develop many effective treatments for diseases found throughout the body, but we’ve yet to have the same success with the brain. The so-called 'blood brain barrier' controls the passage of molecules out of the blood and into the brain, and so it’s not as easy to use the bloodstream to carry therapeutic molecules as we might do for other diseases. Could the blood brain barrier be the key to treating neurological disorders? How can we target this structure to make therapies more effective?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

This Week's Guests

James Choi
James Choi is the Principal Investigator of Non-invasive Surgery and Biopsy Laboratory at Imperial College London and is an Associate Professor in the Department of Bioengineering at the institute. The purpose of the Noninvasive Surgery & Biopsy Laboratory is to build incision-less microsurgical devices and methods to locally deliver drugs to the brain. James Choi is a leading expert on the blood brain barrier and has authored numerous research publications in the fields of noninvasive surgery and delivery through the blood brain barrier using focused ultrasound. James Choi's work at the laboratory is currently focused on treating several dieseases, including Alzheimers, using non-invasive devices for delivering drugs across the blood-brain barrier.

Sam Barker
Sam Barker is the Chief Business Officer at Somaserve, a genetic medicines company that is pioneering new medicines for crossing the blood brain barrier and other biologicial barries. Using a proprietary targeted polymer nanoparticle technology, PolyNaut®, Somaserve is delivering genetic materials to cells and tissues of choice, including targeted delivery to the central nervous system. Sam Barker has deep experience in start-up and growth stage companies across drug development from discovery to delivery, with expertise in developing and commercialising innovative platform technologies.

]]> false full 4 2 c0c8b714-6859-4d3c-bb68-bdbc8e5b2185 <![CDATA[Small Molecules: can new classes of drug target reinvigorate drug discovery?]]> In the pharmaceutical industry, there is a desire to go beyond the traditional ‘compound x acts on protein y,’ and achieve a more nuanced effect on the underlying biology. So, could innovative approaches to small molecules open up a wider application space? And what benefits might this bring to cash-strapped healthcare systems?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Anne Horgan
Anne Horgan is a partner at Cambridge Innovation Captial, a venture capital firm that invest in IP rich businesses in both deep tech and life science. With a robust academic foundation in organic and medicinal chemistry, Anne's career path began in Ph.D and postdoctoral research which culminated into a role in a small cambridge-based company dedicated to the creation of small molecules for therapeutic applications. Her journey then took her into the fascinating domain of technology transfer, where she honed her skills at Cancer Research UK (formerly known as Cancer Research Technology), helping bridge the gap between groundbreaking research and practical applications, now under the banner of Cancer Research Horizons. Now, Anne's expertise and experience has found their home at Cambridge Innovation Capital, where she continues to play an instrumental role in shaping the future of innovation and technology-driven businesses.

Rabia Khan
Rabia Khan is the founder and CEO of Serna Bio. Serna Bio (previously Ladder Therapeutics) is using an AI-based, data-first approach to write the rules that define RNA-small molecule interactions. Rabia's educational pursuit took her from Pakistan to Canada, where she pursued a degree in genetics, followed by a Ph.D and an MBA. Rabia would also go on to complete a postdoc on IPS derived macrophages in the UK. Rabia's passion for genetics stemmed from the elegance of the four-letter genetic code (ATGC) that defines all living beings, eventually leading her to a company called Sensyne Health, working at the intersection of computational methods and patient data to enable drug discovery. Rabia's journey has traversed both geographic and scientific landscapes, now, Rabia's work at Serna Bio is driving towards the world's first map of the druggable transcriptome.

]]> Wed, 04 Oct 2023 08:50:23 -0400 https://ttp.com/invent 40:39 In the pharmaceutical industry, there is a desire to go beyond the traditional ‘compound x acts on protein y,’ and achieve a more nuanced effect on the underlying biology. So, could innovative approaches to small molecules open up a wider application space? And what benefits might this bring to cash-strapped healthcare systems?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Anne Horgan
Anne Horgan is a partner at Cambridge Innovation Captial, a venture capital firm that invest in IP rich businesses in both deep tech and life science. With a robust academic foundation in organic and medicinal chemistry, Anne's career path began in Ph.D and postdoctoral research which culminated into a role in a small cambridge-based company dedicated to the creation of small molecules for therapeutic applications. Her journey then took her into the fascinating domain of technology transfer, where she honed her skills at Cancer Research UK (formerly known as Cancer Research Technology), helping bridge the gap between groundbreaking research and practical applications, now under the banner of Cancer Research Horizons. Now, Anne's expertise and experience has found their home at Cambridge Innovation Capital, where she continues to play an instrumental role in shaping the future of innovation and technology-driven businesses.

Rabia Khan
Rabia Khan is the founder and CEO of Serna Bio. Serna Bio (previously Ladder Therapeutics) is using an AI-based, data-first approach to write the rules that define RNA-small molecule interactions. Rabia's educational pursuit took her from Pakistan to Canada, where she pursued a degree in genetics, followed by a Ph.D and an MBA. Rabia would also go on to complete a postdoc on IPS derived macrophages in the UK. Rabia's passion for genetics stemmed from the elegance of the four-letter genetic code (ATGC) that defines all living beings, eventually leading her to a company called Sensyne Health, working at the intersection of computational methods and patient data to enable drug discovery. Rabia's journey has traversed both geographic and scientific landscapes, now, Rabia's work at Serna Bio is driving towards the world's first map of the druggable transcriptome.

]]> In the pharmaceutical industry, there is a desire to go beyond the traditional ‘compound x acts on protein y,’ and achieve a more nuanced effect on the underlying biology. So, could innovative approaches to small molecules open up a wider application space? And what benefits might this bring to cash-strapped healthcare systems?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Anne Horgan
Anne Horgan is a partner at Cambridge Innovation Captial, a venture capital firm that invest in IP rich businesses in both deep tech and life science. With a robust academic foundation in organic and medicinal chemistry, Anne's career path began in Ph.D and postdoctoral research which culminated into a role in a small cambridge-based company dedicated to the creation of small molecules for therapeutic applications. Her journey then took her into the fascinating domain of technology transfer, where she honed her skills at Cancer Research UK (formerly known as Cancer Research Technology), helping bridge the gap between groundbreaking research and practical applications, now under the banner of Cancer Research Horizons. Now, Anne's expertise and experience has found their home at Cambridge Innovation Capital, where she continues to play an instrumental role in shaping the future of innovation and technology-driven businesses.

Rabia Khan
Rabia Khan is the founder and CEO of Serna Bio. Serna Bio (previously Ladder Therapeutics) is using an AI-based, data-first approach to write the rules that define RNA-small molecule interactions. Rabia's educational pursuit took her from Pakistan to Canada, where she pursued a degree in genetics, followed by a Ph.D and an MBA. Rabia would also go on to complete a postdoc on IPS derived macrophages in the UK. Rabia's passion for genetics stemmed from the elegance of the four-letter genetic code (ATGC) that defines all living beings, eventually leading her to a company called Sensyne Health, working at the intersection of computational methods and patient data to enable drug discovery. Rabia's journey has traversed both geographic and scientific landscapes, now, Rabia's work at Serna Bio is driving towards the world's first map of the druggable transcriptome.

]]> false full 3 2 35fa3664-5d78-4c1d-b866-bfece0c7c2fb <![CDATA[Cell and gene therapy: how can we transform artisan treatments into mass-market cures?]]> Cell and gene therapies are extremely effective but their complex production processes, arduous supply chain, and life-critical logistics have prevented mass market adoption. Could digitisation and AI provide a breakthrough in manufacturing? Would more companies be willing to work together on standardisation to provide more flexibility?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Matthew Durdy
Matthew Durdy is a biologist, investor, entrepreneur, and the Chief Executive of the Cell and Therapy Catapult. Previously responsible for the development of the business and strategy arm of the Cell and Gene Therapy Catapult, Matthew's work now combines three sets of experience: corporate investment banking; new venture and innovation management, and biotechnology leadership, into one passion; creating the environment for, and leading the commercialisation of brilliant science into life-changing products.

Alexander Seyf
Alexander Seyf is a business leader, entrepreneur, and one of the co-founders and CEO of Autolomous. Autolomous offers pragmatic digital solutions for cell and gene therapy manufacturing and was founded in 2019 with a mission to revolutionise cell and gene therapy manufacturing through digital innovation. Alexander brings a unique perspective to this endeavor, drawing from his background in physics, the telecom industry, and extensive experience in management consultancy and startups.

]]> Wed, 27 Sep 2023 11:14:02 -0400 https://ttp.com/invent 37:47 Cell and gene therapies are extremely effective but their complex production processes, arduous supply chain, and life-critical logistics have prevented mass market adoption. Could digitisation and AI provide a breakthrough in manufacturing? Would more companies be willing to work together on standardisation to provide more flexibility?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Matthew Durdy
Matthew Durdy is a biologist, investor, entrepreneur, and the Chief Executive of the Cell and Therapy Catapult. Previously responsible for the development of the business and strategy arm of the Cell and Gene Therapy Catapult, Matthew's work now combines three sets of experience: corporate investment banking; new venture and innovation management, and biotechnology leadership, into one passion; creating the environment for, and leading the commercialisation of brilliant science into life-changing products.

Alexander Seyf
Alexander Seyf is a business leader, entrepreneur, and one of the co-founders and CEO of Autolomous. Autolomous offers pragmatic digital solutions for cell and gene therapy manufacturing and was founded in 2019 with a mission to revolutionise cell and gene therapy manufacturing through digital innovation. Alexander brings a unique perspective to this endeavor, drawing from his background in physics, the telecom industry, and extensive experience in management consultancy and startups.

]]> Cell and gene therapies are extremely effective but their complex production processes, arduous supply chain, and life-critical logistics have prevented mass market adoption. Could digitisation and AI provide a breakthrough in manufacturing? Would more companies be willing to work together on standardisation to provide more flexibility?


To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.


This Week's Guests

Matthew Durdy
Matthew Durdy is a biologist, investor, entrepreneur, and the Chief Executive of the Cell and Therapy Catapult. Previously responsible for the development of the business and strategy arm of the Cell and Gene Therapy Catapult, Matthew's work now combines three sets of experience: corporate investment banking; new venture and innovation management, and biotechnology leadership, into one passion; creating the environment for, and leading the commercialisation of brilliant science into life-changing products.

Alexander Seyf
Alexander Seyf is a business leader, entrepreneur, and one of the co-founders and CEO of Autolomous. Autolomous offers pragmatic digital solutions for cell and gene therapy manufacturing and was founded in 2019 with a mission to revolutionise cell and gene therapy manufacturing through digital innovation. Alexander brings a unique perspective to this endeavor, drawing from his background in physics, the telecom industry, and extensive experience in management consultancy and startups.

]]> false full 2 2 de6ef8e8-89f8-4f8c-9087-adb4eee08b2c <![CDATA[mRNA: What did Covid teach us about drug development and distribution?]]> The Covid vaccination campaign demonstrated the effectiveness of mRNA-based treatments, so what else is this technology capable of? How can we improve our manufacturing and distribution to ensure treatments are available to those who need them most?

 

To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

What is mRNA and what is the importance of mRNA treatments?
Messenger ribonucleic acid, or mRNA for short, is a crucial molecule in the process of making proteins in our bodies. Proteins are essential for the structure, function, and regulation of the cells, tissues, and organs in our bodies.

mRNA treatments, also known as mRNA therapeutics, are a type of medical technology that uses synthetic mRNA to treat or prevent various diseases and medical conditions. Vaccines are one of the most well-known examples of mRNA treatments. These treatments are a relatively new and exciting area of medicine with the potential to revolutionize how we approach healthcare.

This Week's Guests

David Sokolowski
David Sokolowski is the Global Workflow Manager for the Nucleic Acid Therapeutics business unit within Cytiva. Cytiva is a global life sciences leader dedicated to helping customers discover and commercialise the next generation of therapeutics. David has been closely monitoring the RNA field and its evolving applications and manufacturing technologies.

Dan Peer
Dan Peer is a Professor at Tel Aviv University and the Director of the Laboratory of Precision Nanomedicine at Tel Aviv. Dan has been actively engaging in nanomedicine for the past 20 years and is also the university's Vice President for Research and Development. Dan is at the forefront of mRNA research and shares his insight on the rapid expansion of mRNA applications.

]]> Wed, 20 Sep 2023 08:43:04 -0400 https://ttp.com/invent 38:05 The Covid vaccination campaign demonstrated the effectiveness of mRNA-based treatments, so what else is this technology capable of? How can we improve our manufacturing and distribution to ensure treatments are available to those who need them most?

 

To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

What is mRNA and what is the importance of mRNA treatments?
Messenger ribonucleic acid, or mRNA for short, is a crucial molecule in the process of making proteins in our bodies. Proteins are essential for the structure, function, and regulation of the cells, tissues, and organs in our bodies.

mRNA treatments, also known as mRNA therapeutics, are a type of medical technology that uses synthetic mRNA to treat or prevent various diseases and medical conditions. Vaccines are one of the most well-known examples of mRNA treatments. These treatments are a relatively new and exciting area of medicine with the potential to revolutionize how we approach healthcare.

This Week's Guests

David Sokolowski
David Sokolowski is the Global Workflow Manager for the Nucleic Acid Therapeutics business unit within Cytiva. Cytiva is a global life sciences leader dedicated to helping customers discover and commercialise the next generation of therapeutics. David has been closely monitoring the RNA field and its evolving applications and manufacturing technologies.

Dan Peer
Dan Peer is a Professor at Tel Aviv University and the Director of the Laboratory of Precision Nanomedicine at Tel Aviv. Dan has been actively engaging in nanomedicine for the past 20 years and is also the university's Vice President for Research and Development. Dan is at the forefront of mRNA research and shares his insight on the rapid expansion of mRNA applications.

]]> The Covid vaccination campaign demonstrated the effectiveness of mRNA-based treatments, so what else is this technology capable of? How can we improve our manufacturing and distribution to ensure treatments are available to those who need them most?

 

To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.

What is mRNA and what is the importance of mRNA treatments?
Messenger ribonucleic acid, or mRNA for short, is a crucial molecule in the process of making proteins in our bodies. Proteins are essential for the structure, function, and regulation of the cells, tissues, and organs in our bodies.

mRNA treatments, also known as mRNA therapeutics, are a type of medical technology that uses synthetic mRNA to treat or prevent various diseases and medical conditions. Vaccines are one of the most well-known examples of mRNA treatments. These treatments are a relatively new and exciting area of medicine with the potential to revolutionize how we approach healthcare.

This Week's Guests

David Sokolowski
David Sokolowski is the Global Workflow Manager for the Nucleic Acid Therapeutics business unit within Cytiva. Cytiva is a global life sciences leader dedicated to helping customers discover and commercialise the next generation of therapeutics. David has been closely monitoring the RNA field and its evolving applications and manufacturing technologies.

Dan Peer
Dan Peer is a Professor at Tel Aviv University and the Director of the Laboratory of Precision Nanomedicine at Tel Aviv. Dan has been actively engaging in nanomedicine for the past 20 years and is also the university's Vice President for Research and Development. Dan is at the forefront of mRNA research and shares his insight on the rapid expansion of mRNA applications.

]]> false full 1 2 889e428e-2910-4f17-a57c-ea3b2032faee <![CDATA[Introducing Invent: Life Science Series 2]]> Invent: Life Sciences is back for Season 2! 

Invent: Life Sciences is a podcast about the future of life science and technology, hosted by Head of Cell Gene Therapy and Biotechnology at TTP, Stuart Lowe.

Each episode, we’ll be joined by the top scientists, designers, business leaders, and academics working at the vanguard of this vital industry, to give you a behind-the-scenes look at the world of life science.

In this new season, we now turn our focus onto advances driving forward the pharmaceutical sector, and how life scientists are dedicating their lives to bringing the benefits of medicine to those who need it most.

Listen to the full trailer now!

]]> Wed, 13 Sep 2023 07:32:02 -0400 https://ttp.com/invent 2:37 Invent: Life Sciences is back for Season 2! 

Invent: Life Sciences is a podcast about the future of life science and technology, hosted by Head of Cell Gene Therapy and Biotechnology at TTP, Stuart Lowe.

Each episode, we’ll be joined by the top scientists, designers, business leaders, and academics working at the vanguard of this vital industry, to give you a behind-the-scenes look at the world of life science.

In this new season, we now turn our focus onto advances driving forward the pharmaceutical sector, and how life scientists are dedicating their lives to bringing the benefits of medicine to those who need it most.

Listen to the full trailer now!

]]> Invent: Life Sciences is back for Season 2! 

Invent: Life Sciences is a podcast about the future of life science and technology, hosted by Head of Cell Gene Therapy and Biotechnology at TTP, Stuart Lowe.

Each episode, we’ll be joined by the top scientists, designers, business leaders, and academics working at the vanguard of this vital industry, to give you a behind-the-scenes look at the world of life science.

In this new season, we now turn our focus onto advances driving forward the pharmaceutical sector, and how life scientists are dedicating their lives to bringing the benefits of medicine to those who need it most.

Listen to the full trailer now!

]]> false trailer 2 ec04fd1b-0161-43b6-ae78-8d68581c22ca <![CDATA[Introducing Invent: Health Series 2]]> Calling all Invent: Life Sciences Subscribers! While you wait for more episodes, make sure to subscribe to our sister podcast, Invent: Health, which has just begun its second season. Listen to the trailer here now!

 

Invent: Health sees host Matt Parker explore the fascinating future of Health technologies. From new closed-loop systems for diabetes to sensing innovations in cardiac health, Matt will be taking a look behind the scenes of these technologies and meeting the people working to transform our collective health.

Listen and subscribe from anywhere you get your podcasts, just search 'Invent: Health'.

You can also follow the Invent: Health series from our Transistor page and listen to the recent episode on the future of epilepsy treatment: inventhealth.transistor.fm

The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: www.ttp.com

]]> Mon, 13 Feb 2023 10:56:27 -0500 https://ttp.com/invent 2:45 Calling all Invent: Life Sciences Subscribers! While you wait for more episodes, make sure to subscribe to our sister podcast, Invent: Health, which has just begun its second season. Listen to the trailer here now!

 

Invent: Health sees host Matt Parker explore the fascinating future of Health technologies. From new closed-loop systems for diabetes to sensing innovations in cardiac health, Matt will be taking a look behind the scenes of these technologies and meeting the people working to transform our collective health.

Listen and subscribe from anywhere you get your podcasts, just search 'Invent: Health'.

You can also follow the Invent: Health series from our Transistor page and listen to the recent episode on the future of epilepsy treatment: inventhealth.transistor.fm

The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: www.ttp.com

]]> Calling all Invent: Life Sciences Subscribers! While you wait for more episodes, make sure to subscribe to our sister podcast, Invent: Health, which has just begun its second season. Listen to the trailer here now!

 

Invent: Health sees host Matt Parker explore the fascinating future of Health technologies. From new closed-loop systems for diabetes to sensing innovations in cardiac health, Matt will be taking a look behind the scenes of these technologies and meeting the people working to transform our collective health.

Listen and subscribe from anywhere you get your podcasts, just search 'Invent: Health'.

You can also follow the Invent: Health series from our Transistor page and listen to the recent episode on the future of epilepsy treatment: inventhealth.transistor.fm

The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: www.ttp.com

]]> false trailer 2 87177864-6e72-4836-b98b-991965cf7bcf <![CDATA[Life Science Investment: How to invest in change]]> The pandemic drastically altered the landscape for investment flowing into the Life Sciences. Not only was there more money going in, but the market needs changed too, with an unprecedented focus on scaling sectors like testing and vaccines. But what did this mean for sectors which were not on the Covid front line? What happened to the trends that were in train before the pandemic hit? And what have we learnt from this experience that we can deploy in the face of the next global challenge? In this episode of Invent: Life Sciences, we look at the past, present and future of investing in the sector, to explore the profound effects that the pandemic has had on it as a whole - and find that, when we pull together, amazing things can happen.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Gonzalo Garcia
Gonzalo Garcia is a Biotech investor, company builder and partner at Syncona limited. Syncona are a company who found, build and fund early stage companies to turn science into transformational treatments, in fields ranging from cell and gene, to biologics and small molecule. Prior to this, Gonzalo completed a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and was a project leader at Boston Consulting Group. His work at Syncona includes his role as Chief of Staff and Board observer at Resolution Therapeutics.
https://www.linkedin.com/in/gonzaloagarciag/?originalSubdomain=uk

Dr. Jason Mellad
Jason Mellad is the CEO and co-founder of Start Codon. After a phd in medicine from the University of Cambridge, Jason worked in various directing roles for a number of exciting Life Sciences companies, like Cambridge Epigenetics, before founding Start Codon in late 2018. Start Codon are a venture capital investor and venture builder who support aspiring entrepreneurs in development and commercialisation of their businesses. They look for the most disruptive innovations in the life sciences space, and have already seen dozens of successful start ups come through their programme to bring their ideas to the world.
https://www.linkedin.com/in/jason-mellad-54890622/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 19 Jul 2022 07:00:00 -0400 https://ttp.com/invent 44:24 The pandemic drastically altered the landscape for investment flowing into the Life Sciences. Not only was there more money going in, but the market needs changed too, with an unprecedented focus on scaling sectors like testing and vaccines. But what did this mean for sectors which were not on the Covid front line? What happened to the trends that were in train before the pandemic hit? And what have we learnt from this experience that we can deploy in the face of the next global challenge? In this episode of Invent: Life Sciences, we look at the past, present and future of investing in the sector, to explore the profound effects that the pandemic has had on it as a whole - and find that, when we pull together, amazing things can happen.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Gonzalo Garcia
Gonzalo Garcia is a Biotech investor, company builder and partner at Syncona limited. Syncona are a company who found, build and fund early stage companies to turn science into transformational treatments, in fields ranging from cell and gene, to biologics and small molecule. Prior to this, Gonzalo completed a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and was a project leader at Boston Consulting Group. His work at Syncona includes his role as Chief of Staff and Board observer at Resolution Therapeutics.
https://www.linkedin.com/in/gonzaloagarciag/?originalSubdomain=uk

Dr. Jason Mellad
Jason Mellad is the CEO and co-founder of Start Codon. After a phd in medicine from the University of Cambridge, Jason worked in various directing roles for a number of exciting Life Sciences companies, like Cambridge Epigenetics, before founding Start Codon in late 2018. Start Codon are a venture capital investor and venture builder who support aspiring entrepreneurs in development and commercialisation of their businesses. They look for the most disruptive innovations in the life sciences space, and have already seen dozens of successful start ups come through their programme to bring their ideas to the world.
https://www.linkedin.com/in/jason-mellad-54890622/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> The pandemic drastically altered the landscape for investment flowing into the Life Sciences. Not only was there more money going in, but the market needs changed too, with an unprecedented focus on scaling sectors like testing and vaccines. But what did this mean for sectors which were not on the Covid front line? What happened to the trends that were in train before the pandemic hit? And what have we learnt from this experience that we can deploy in the face of the next global challenge? In this episode of Invent: Life Sciences, we look at the past, present and future of investing in the sector, to explore the profound effects that the pandemic has had on it as a whole - and find that, when we pull together, amazing things can happen.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Gonzalo Garcia
Gonzalo Garcia is a Biotech investor, company builder and partner at Syncona limited. Syncona are a company who found, build and fund early stage companies to turn science into transformational treatments, in fields ranging from cell and gene, to biologics and small molecule. Prior to this, Gonzalo completed a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and was a project leader at Boston Consulting Group. His work at Syncona includes his role as Chief of Staff and Board observer at Resolution Therapeutics.
https://www.linkedin.com/in/gonzaloagarciag/?originalSubdomain=uk

Dr. Jason Mellad
Jason Mellad is the CEO and co-founder of Start Codon. After a phd in medicine from the University of Cambridge, Jason worked in various directing roles for a number of exciting Life Sciences companies, like Cambridge Epigenetics, before founding Start Codon in late 2018. Start Codon are a venture capital investor and venture builder who support aspiring entrepreneurs in development and commercialisation of their businesses. They look for the most disruptive innovations in the life sciences space, and have already seen dozens of successful start ups come through their programme to bring their ideas to the world.
https://www.linkedin.com/in/jason-mellad-54890622/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 8 1 eb873666-62ac-4456-9405-3046e03e174a <![CDATA[Diagnostics: How to do self-testing better]]> In the past decade, two events have sent shockwaves through the diagnostics industry: Theranos and Covid. The first, is a parable against faking it in an industry which rightly prizes accuracy and safety. The second was an almost insatiable demand for diagnostic testing kits, where the speed of information took second place to accuracy. Was Elizabeth Holmes onto something when she founded Theranos? What if her devices had been able to live up to the hype? And what reputation does self-testing now have in the diagnostics industry? In this episode of Invent Life Sciences, we take a look at the Theranos story and the Covid pandemic and see what lessons can be learned from each.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests


Professor Tony Cass

Tony is a professor of chemical biology at Imperial College London, an institution he has been a part of for the best part of three decades. Alongside his fellowship of the Royal Society of Chemistry, Tony pioneered the use of synthetic electron transfer mediators for enzyme biosensors, and his work in this area led to the development of the first electronic blood glucose measuring system. 
https://www.linkedin.com/in/tonycass/?originalSubdomain=uk


Dr. Giles Sanders
Giles is the head of In Vitro diagnostics at TTP and has been with us for two decades. During that time he has been influential in the development of numerous diagnostics systems that have been successfully placed on the market. He works across all aspects of In Vitro diagnostics, from automated central lab, to point of care and home use devices. 
https://www.linkedin.com/in/gilessanders/?originalSubdomain=uk


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 12 Jul 2022 07:00:00 -0400 https://ttp.com/invent 48:11 In the past decade, two events have sent shockwaves through the diagnostics industry: Theranos and Covid. The first, is a parable against faking it in an industry which rightly prizes accuracy and safety. The second was an almost insatiable demand for diagnostic testing kits, where the speed of information took second place to accuracy. Was Elizabeth Holmes onto something when she founded Theranos? What if her devices had been able to live up to the hype? And what reputation does self-testing now have in the diagnostics industry? In this episode of Invent Life Sciences, we take a look at the Theranos story and the Covid pandemic and see what lessons can be learned from each.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests


Professor Tony Cass

Tony is a professor of chemical biology at Imperial College London, an institution he has been a part of for the best part of three decades. Alongside his fellowship of the Royal Society of Chemistry, Tony pioneered the use of synthetic electron transfer mediators for enzyme biosensors, and his work in this area led to the development of the first electronic blood glucose measuring system. 
https://www.linkedin.com/in/tonycass/?originalSubdomain=uk


Dr. Giles Sanders
Giles is the head of In Vitro diagnostics at TTP and has been with us for two decades. During that time he has been influential in the development of numerous diagnostics systems that have been successfully placed on the market. He works across all aspects of In Vitro diagnostics, from automated central lab, to point of care and home use devices. 
https://www.linkedin.com/in/gilessanders/?originalSubdomain=uk


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> In the past decade, two events have sent shockwaves through the diagnostics industry: Theranos and Covid. The first, is a parable against faking it in an industry which rightly prizes accuracy and safety. The second was an almost insatiable demand for diagnostic testing kits, where the speed of information took second place to accuracy. Was Elizabeth Holmes onto something when she founded Theranos? What if her devices had been able to live up to the hype? And what reputation does self-testing now have in the diagnostics industry? In this episode of Invent Life Sciences, we take a look at the Theranos story and the Covid pandemic and see what lessons can be learned from each.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests


Professor Tony Cass

Tony is a professor of chemical biology at Imperial College London, an institution he has been a part of for the best part of three decades. Alongside his fellowship of the Royal Society of Chemistry, Tony pioneered the use of synthetic electron transfer mediators for enzyme biosensors, and his work in this area led to the development of the first electronic blood glucose measuring system. 
https://www.linkedin.com/in/tonycass/?originalSubdomain=uk


Dr. Giles Sanders
Giles is the head of In Vitro diagnostics at TTP and has been with us for two decades. During that time he has been influential in the development of numerous diagnostics systems that have been successfully placed on the market. He works across all aspects of In Vitro diagnostics, from automated central lab, to point of care and home use devices. 
https://www.linkedin.com/in/gilessanders/?originalSubdomain=uk


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 7 1 780b4131-a1df-4ad9-9330-1b2d017f30a6 <![CDATA[Cell Therapy Manufacture: How to scale the manufacture of living drugs]]> Following our first episode of two focusing on cell and gene therapies, outlining the promise and practicalities of delivering curative therapies for chronic diseases, we now focus on cell therapies - so called ‘living drugs’ that are both as powerful as they are complex. Despite the impressive trials and life-changing impacts at the individual level, it’s still not possible to manufacture cell therapies at scales that could benefit a wider range of patients. So what are the differences between cell therapies and conventional medicines that make them so difficult to manufacture? Can we redeploy hardware and learnings from other industries or are custom solutions needed? And does the ‘where’ we manufacture these therapies matter more than the ‘how’? As we discover in this episode, efforts to address these questions and provide scalable manufacturing solutions could unleash a new wave of pharmaceutical innovation that promises to revolutionise the way we develop medicines.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Edwin Stone

Ed is our head of cell and gene at TTP. After a PHD specialising in Vehicle Dynamics from the University of Cambridge, Ed started working at TTP some 18 years ago, most of which has been spent specialising in cell and gene. He’s been focusing on the manufacturing realm of cell and gene for the past seven years. His work spans everything from commercial strategy through to technology development and on to production.

https://www.linkedin.com/in/edwin-stone-98560212/

Mike Lehmicke
Mike is the Senior Director of Science and Industry Affairs at the Alliance for Regenerative Medicine, and has over 20 years of R&D experience in biomaterials, medical devices, and regenerative medicine. His work focuses on cell based tissue engineering, bioceramics and medicines which have the ability to help repair or replace damaged human cells or tissues.
https://www.linkedin.com/in/michael-lehmicke-76b45435/


Dr. Félix A. Montero-Julian
Félix is a Scientific Director of the Healthcare Business of bioMérieux. With over 25 years of experience in industrial and clinical diagnostics, Félix is extensively involved in the implementation and acceptance of rapid and alternative microbiological methods, with an array of technical experience across the cell and gene therapy manufacturing process.
https://www.linkedin.com/in/f%C3%A9lix-a-montero-julian-phd-0a3a501b/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 05 Jul 2022 07:00:00 -0400 https://ttp.com/invent 46:27 Following our first episode of two focusing on cell and gene therapies, outlining the promise and practicalities of delivering curative therapies for chronic diseases, we now focus on cell therapies - so called ‘living drugs’ that are both as powerful as they are complex. Despite the impressive trials and life-changing impacts at the individual level, it’s still not possible to manufacture cell therapies at scales that could benefit a wider range of patients. So what are the differences between cell therapies and conventional medicines that make them so difficult to manufacture? Can we redeploy hardware and learnings from other industries or are custom solutions needed? And does the ‘where’ we manufacture these therapies matter more than the ‘how’? As we discover in this episode, efforts to address these questions and provide scalable manufacturing solutions could unleash a new wave of pharmaceutical innovation that promises to revolutionise the way we develop medicines.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Edwin Stone

Ed is our head of cell and gene at TTP. After a PHD specialising in Vehicle Dynamics from the University of Cambridge, Ed started working at TTP some 18 years ago, most of which has been spent specialising in cell and gene. He’s been focusing on the manufacturing realm of cell and gene for the past seven years. His work spans everything from commercial strategy through to technology development and on to production.

https://www.linkedin.com/in/edwin-stone-98560212/

Mike Lehmicke
Mike is the Senior Director of Science and Industry Affairs at the Alliance for Regenerative Medicine, and has over 20 years of R&D experience in biomaterials, medical devices, and regenerative medicine. His work focuses on cell based tissue engineering, bioceramics and medicines which have the ability to help repair or replace damaged human cells or tissues.
https://www.linkedin.com/in/michael-lehmicke-76b45435/


Dr. Félix A. Montero-Julian
Félix is a Scientific Director of the Healthcare Business of bioMérieux. With over 25 years of experience in industrial and clinical diagnostics, Félix is extensively involved in the implementation and acceptance of rapid and alternative microbiological methods, with an array of technical experience across the cell and gene therapy manufacturing process.
https://www.linkedin.com/in/f%C3%A9lix-a-montero-julian-phd-0a3a501b/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Following our first episode of two focusing on cell and gene therapies, outlining the promise and practicalities of delivering curative therapies for chronic diseases, we now focus on cell therapies - so called ‘living drugs’ that are both as powerful as they are complex. Despite the impressive trials and life-changing impacts at the individual level, it’s still not possible to manufacture cell therapies at scales that could benefit a wider range of patients. So what are the differences between cell therapies and conventional medicines that make them so difficult to manufacture? Can we redeploy hardware and learnings from other industries or are custom solutions needed? And does the ‘where’ we manufacture these therapies matter more than the ‘how’? As we discover in this episode, efforts to address these questions and provide scalable manufacturing solutions could unleash a new wave of pharmaceutical innovation that promises to revolutionise the way we develop medicines.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Edwin Stone

Ed is our head of cell and gene at TTP. After a PHD specialising in Vehicle Dynamics from the University of Cambridge, Ed started working at TTP some 18 years ago, most of which has been spent specialising in cell and gene. He’s been focusing on the manufacturing realm of cell and gene for the past seven years. His work spans everything from commercial strategy through to technology development and on to production.

https://www.linkedin.com/in/edwin-stone-98560212/

Mike Lehmicke
Mike is the Senior Director of Science and Industry Affairs at the Alliance for Regenerative Medicine, and has over 20 years of R&D experience in biomaterials, medical devices, and regenerative medicine. His work focuses on cell based tissue engineering, bioceramics and medicines which have the ability to help repair or replace damaged human cells or tissues.
https://www.linkedin.com/in/michael-lehmicke-76b45435/


Dr. Félix A. Montero-Julian
Félix is a Scientific Director of the Healthcare Business of bioMérieux. With over 25 years of experience in industrial and clinical diagnostics, Félix is extensively involved in the implementation and acceptance of rapid and alternative microbiological methods, with an array of technical experience across the cell and gene therapy manufacturing process.
https://www.linkedin.com/in/f%C3%A9lix-a-montero-julian-phd-0a3a501b/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 6 1 0a335bbe-7977-454d-8890-b2b8407d0d44 <![CDATA[Cell and Gene: How to make advanced therapies accessible]]> With therapies like cell and gene - amongst some of the most significant innovations in modern medicine - the idea of delivering cures for conditions from cancer to diabetes is now within the realm of scientific possibility. But will it be possible to provide the benefits of advanced therapies to all? Should we expect our healthcare systems to foot the bill? And can we re-imagine the development ecosystem to truly realise the potential of cell and gene therapies? In this first of two episodes about curing diseases and cell & gene therapies, we outline why we would want to treat diseases in this way, the main economic barriers to achieving it, and where these exciting new therapies are going next.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests


Dr. Dan Strange
Dan is a technologist and engineering leader with a background in tissue biomechanics, regenerative medicine, and mechanical engineering. He's been at TTP for the past decade, driving forward large development programs from start to finish, as well as being a huge advocate for cell and gene therapies.
https://www.linkedin.com/in/drdanstrange/


Professor Jacob Petersen
Jacob is the head of cell therapy research & development at Novo Nordisk and an adjunct professor in biomedicine at Copenhagen University Medical Faculty. With over 20 years in the pharmaceutical and biotechnology spaces, Jacob has worked in R&D for everything from diabetes to cardiovascular disease, and through his current head of cell therapy R&D role, he is involved in the creation of new treatments in this space from start to finish. 

https://www.linkedin.com/in/jacob-petersen-820529/

Dr. Kath Mackay
Kath is the director of Life Sciences for Bruntwood SciTech, a company that provides companies with the infrastructure around Cell and Gene. Previously on the executive management team at Innovate UK, Kath has a track record which proves her passion for growing the UK’s life sciences sector, and in her new role is responsible for developing Bruntwood SciTech’s life sciences vision, strategy and services in their campuses, which includes Alderley Park, Birmingham Health Innovation Campus, Citylabs, Manchester and Melbourn Science Park.
https://www.linkedin.com/in/drkathmackay/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 28 Jun 2022 07:00:00 -0400 https://ttp.com/invent 47:16 With therapies like cell and gene - amongst some of the most significant innovations in modern medicine - the idea of delivering cures for conditions from cancer to diabetes is now within the realm of scientific possibility. But will it be possible to provide the benefits of advanced therapies to all? Should we expect our healthcare systems to foot the bill? And can we re-imagine the development ecosystem to truly realise the potential of cell and gene therapies? In this first of two episodes about curing diseases and cell & gene therapies, we outline why we would want to treat diseases in this way, the main economic barriers to achieving it, and where these exciting new therapies are going next.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests


Dr. Dan Strange
Dan is a technologist and engineering leader with a background in tissue biomechanics, regenerative medicine, and mechanical engineering. He's been at TTP for the past decade, driving forward large development programs from start to finish, as well as being a huge advocate for cell and gene therapies.
https://www.linkedin.com/in/drdanstrange/


Professor Jacob Petersen
Jacob is the head of cell therapy research & development at Novo Nordisk and an adjunct professor in biomedicine at Copenhagen University Medical Faculty. With over 20 years in the pharmaceutical and biotechnology spaces, Jacob has worked in R&D for everything from diabetes to cardiovascular disease, and through his current head of cell therapy R&D role, he is involved in the creation of new treatments in this space from start to finish. 

https://www.linkedin.com/in/jacob-petersen-820529/

Dr. Kath Mackay
Kath is the director of Life Sciences for Bruntwood SciTech, a company that provides companies with the infrastructure around Cell and Gene. Previously on the executive management team at Innovate UK, Kath has a track record which proves her passion for growing the UK’s life sciences sector, and in her new role is responsible for developing Bruntwood SciTech’s life sciences vision, strategy and services in their campuses, which includes Alderley Park, Birmingham Health Innovation Campus, Citylabs, Manchester and Melbourn Science Park.
https://www.linkedin.com/in/drkathmackay/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> With therapies like cell and gene - amongst some of the most significant innovations in modern medicine - the idea of delivering cures for conditions from cancer to diabetes is now within the realm of scientific possibility. But will it be possible to provide the benefits of advanced therapies to all? Should we expect our healthcare systems to foot the bill? And can we re-imagine the development ecosystem to truly realise the potential of cell and gene therapies? In this first of two episodes about curing diseases and cell & gene therapies, we outline why we would want to treat diseases in this way, the main economic barriers to achieving it, and where these exciting new therapies are going next.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests


Dr. Dan Strange
Dan is a technologist and engineering leader with a background in tissue biomechanics, regenerative medicine, and mechanical engineering. He's been at TTP for the past decade, driving forward large development programs from start to finish, as well as being a huge advocate for cell and gene therapies.
https://www.linkedin.com/in/drdanstrange/


Professor Jacob Petersen
Jacob is the head of cell therapy research & development at Novo Nordisk and an adjunct professor in biomedicine at Copenhagen University Medical Faculty. With over 20 years in the pharmaceutical and biotechnology spaces, Jacob has worked in R&D for everything from diabetes to cardiovascular disease, and through his current head of cell therapy R&D role, he is involved in the creation of new treatments in this space from start to finish. 

https://www.linkedin.com/in/jacob-petersen-820529/

Dr. Kath Mackay
Kath is the director of Life Sciences for Bruntwood SciTech, a company that provides companies with the infrastructure around Cell and Gene. Previously on the executive management team at Innovate UK, Kath has a track record which proves her passion for growing the UK’s life sciences sector, and in her new role is responsible for developing Bruntwood SciTech’s life sciences vision, strategy and services in their campuses, which includes Alderley Park, Birmingham Health Innovation Campus, Citylabs, Manchester and Melbourn Science Park.
https://www.linkedin.com/in/drkathmackay/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 5 1 a08bfc95-d5f5-47e9-9289-343ade1b1edc <![CDATA[Preclinical drug development: How to simulate the human body]]> From cosmetics to medicines, animal testing is still widely mandated by regulators. Up to now, there have been few other ways to gather information about the potential human response to drug candidates. But are animal models still the most effective way to test drugs before we use them in humans? Or are these in vivo models outdated, ready to be replaced by innovative new in vitro models of drug development? In this episode of TTP Invent: Life Sciences, we take a look at some of the fascinating alternatives to animal testing in drug development, before assessing what new realms of medicine these new methods could soon open up - from replicating your organs on a chip, to regenerating entire tissues.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Professor Molly Stevens FRS FRENG

Molly is Professor of Biomedical Materials and Regenerative Medicine in the Departments of Materials and Bioengineering at Imperial College London. Following a postdoc working on tissue engineering methods with Bob Langer at MIT, Molly set up her own group at Imperial in 2004. The Stevens Group is a multidisciplinary research group using innovative bioengineering approaches to address key problems in regenerative medicine and biosensing.
https://www.linkedin.com/in/molly-stevens-81742822/


Dr. Lorna Ewart
Lorna is the CSO at Emulate, a company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Lorna is passionate about the pursuit of drug discovery and development. After working in the Microphysiological Systems Centre of Excellence within AstraZeneca, and beginning her own firm Veroli Consulting, Lorna is now renowned for her expertise in Organ-Chips and Organoids.
https://www.linkedin.com/in/lornaewart/


Professor Maria Kavallaris

Maria is best known for her pioneering work in children's cancer. Last year she and collaborator Justin Gooding were awarded the Australian Museum Eureka Prizes for their contribution to a 3D bioprinting technology that promises to revolutionise cancer research, and her work on tumour cells, drug resistance, nanotechnologies and bioprinting have produced countless new discoveries to the field.
https://www.linkedin.com/in/mariakavallaris/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 21 Jun 2022 07:00:00 -0400 https://ttp.com/invent 45:12 From cosmetics to medicines, animal testing is still widely mandated by regulators. Up to now, there have been few other ways to gather information about the potential human response to drug candidates. But are animal models still the most effective way to test drugs before we use them in humans? Or are these in vivo models outdated, ready to be replaced by innovative new in vitro models of drug development? In this episode of TTP Invent: Life Sciences, we take a look at some of the fascinating alternatives to animal testing in drug development, before assessing what new realms of medicine these new methods could soon open up - from replicating your organs on a chip, to regenerating entire tissues.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Professor Molly Stevens FRS FRENG

Molly is Professor of Biomedical Materials and Regenerative Medicine in the Departments of Materials and Bioengineering at Imperial College London. Following a postdoc working on tissue engineering methods with Bob Langer at MIT, Molly set up her own group at Imperial in 2004. The Stevens Group is a multidisciplinary research group using innovative bioengineering approaches to address key problems in regenerative medicine and biosensing.
https://www.linkedin.com/in/molly-stevens-81742822/


Dr. Lorna Ewart
Lorna is the CSO at Emulate, a company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Lorna is passionate about the pursuit of drug discovery and development. After working in the Microphysiological Systems Centre of Excellence within AstraZeneca, and beginning her own firm Veroli Consulting, Lorna is now renowned for her expertise in Organ-Chips and Organoids.
https://www.linkedin.com/in/lornaewart/


Professor Maria Kavallaris

Maria is best known for her pioneering work in children's cancer. Last year she and collaborator Justin Gooding were awarded the Australian Museum Eureka Prizes for their contribution to a 3D bioprinting technology that promises to revolutionise cancer research, and her work on tumour cells, drug resistance, nanotechnologies and bioprinting have produced countless new discoveries to the field.
https://www.linkedin.com/in/mariakavallaris/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> From cosmetics to medicines, animal testing is still widely mandated by regulators. Up to now, there have been few other ways to gather information about the potential human response to drug candidates. But are animal models still the most effective way to test drugs before we use them in humans? Or are these in vivo models outdated, ready to be replaced by innovative new in vitro models of drug development? In this episode of TTP Invent: Life Sciences, we take a look at some of the fascinating alternatives to animal testing in drug development, before assessing what new realms of medicine these new methods could soon open up - from replicating your organs on a chip, to regenerating entire tissues.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Professor Molly Stevens FRS FRENG

Molly is Professor of Biomedical Materials and Regenerative Medicine in the Departments of Materials and Bioengineering at Imperial College London. Following a postdoc working on tissue engineering methods with Bob Langer at MIT, Molly set up her own group at Imperial in 2004. The Stevens Group is a multidisciplinary research group using innovative bioengineering approaches to address key problems in regenerative medicine and biosensing.
https://www.linkedin.com/in/molly-stevens-81742822/


Dr. Lorna Ewart
Lorna is the CSO at Emulate, a company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. Lorna is passionate about the pursuit of drug discovery and development. After working in the Microphysiological Systems Centre of Excellence within AstraZeneca, and beginning her own firm Veroli Consulting, Lorna is now renowned for her expertise in Organ-Chips and Organoids.
https://www.linkedin.com/in/lornaewart/


Professor Maria Kavallaris

Maria is best known for her pioneering work in children's cancer. Last year she and collaborator Justin Gooding were awarded the Australian Museum Eureka Prizes for their contribution to a 3D bioprinting technology that promises to revolutionise cancer research, and her work on tumour cells, drug resistance, nanotechnologies and bioprinting have produced countless new discoveries to the field.
https://www.linkedin.com/in/mariakavallaris/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 4 1 13e227ce-8615-4403-b668-4fcff288b47d <![CDATA[AI: How to think differently]]> The hunt to discover new pharmaceuticals in areas of high unmet need can be complex, time-consuming, and costly. For every life saving therapy that hits the market, thousands and even millions of candidate drugs are rejected. A new technology could be changing the way we home in on the most effective therapy: AI. The use of AI in drug discovery - whether through mining research or in highlighting new experimental insight - is one of the most exciting new sectors in the field. But how does it really work? What are the conditions needed to implement it? Is it really anything more than just a useful tool? In this episode of Invent: Life Sciences from TTP, we take a look at this fascinating new frontier for drug discovery.


Find out more on this week's episode of Invent: Life Sciences from TTP.


This Week's Guests

Dr. Sarah Morrow
Sarah is a Life Sciences Consultant at TTP, joining in 2020 after getting her PhD specialising in Organic Chemistry from the University of Oxford. Sarah brings a chemist’s perspective on the challenges encountered within drug discovery, as well as focusing on the technology - both hardware and software - that could enable and accelerate the field.
https://www.linkedin.com/in/sarah-morrow-841719146/

Aaron Morris
Aaron Morris is the CEO and co-founder of PostEra, a company building an end-to-end medicinal chemistry platform to advance drug discovery, using machine learning and AI to do so. After seeing the limiting nature of drug discovery on bio tech companies and pharma, Aaron set up PostEra to come in at this early stage and work alongside them to reduce these issues, and to serve the world's ever expanding community of drug hunters.
https://postera.ai/

Dr. Andreas Bender
Andreas Bender is a Professor of Life Sciences informatics interested in developing new life science data analysis methods for their application in drug discovery. After over a decade at Cambridge University working in molecular informatics, Andreas is now the CSO at Terra Lumina, a company building the world’s largest dataset of natural compounds, using AI that unlocks the connection between nature’s small molecules and the human body.
https://terralumina.bio/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 14 Jun 2022 07:00:00 -0400 https://ttp.com/invent 47:52 The hunt to discover new pharmaceuticals in areas of high unmet need can be complex, time-consuming, and costly. For every life saving therapy that hits the market, thousands and even millions of candidate drugs are rejected. A new technology could be changing the way we home in on the most effective therapy: AI. The use of AI in drug discovery - whether through mining research or in highlighting new experimental insight - is one of the most exciting new sectors in the field. But how does it really work? What are the conditions needed to implement it? Is it really anything more than just a useful tool? In this episode of Invent: Life Sciences from TTP, we take a look at this fascinating new frontier for drug discovery.


Find out more on this week's episode of Invent: Life Sciences from TTP.


This Week's Guests

Dr. Sarah Morrow
Sarah is a Life Sciences Consultant at TTP, joining in 2020 after getting her PhD specialising in Organic Chemistry from the University of Oxford. Sarah brings a chemist’s perspective on the challenges encountered within drug discovery, as well as focusing on the technology - both hardware and software - that could enable and accelerate the field.
https://www.linkedin.com/in/sarah-morrow-841719146/

Aaron Morris
Aaron Morris is the CEO and co-founder of PostEra, a company building an end-to-end medicinal chemistry platform to advance drug discovery, using machine learning and AI to do so. After seeing the limiting nature of drug discovery on bio tech companies and pharma, Aaron set up PostEra to come in at this early stage and work alongside them to reduce these issues, and to serve the world's ever expanding community of drug hunters.
https://postera.ai/

Dr. Andreas Bender
Andreas Bender is a Professor of Life Sciences informatics interested in developing new life science data analysis methods for their application in drug discovery. After over a decade at Cambridge University working in molecular informatics, Andreas is now the CSO at Terra Lumina, a company building the world’s largest dataset of natural compounds, using AI that unlocks the connection between nature’s small molecules and the human body.
https://terralumina.bio/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> The hunt to discover new pharmaceuticals in areas of high unmet need can be complex, time-consuming, and costly. For every life saving therapy that hits the market, thousands and even millions of candidate drugs are rejected. A new technology could be changing the way we home in on the most effective therapy: AI. The use of AI in drug discovery - whether through mining research or in highlighting new experimental insight - is one of the most exciting new sectors in the field. But how does it really work? What are the conditions needed to implement it? Is it really anything more than just a useful tool? In this episode of Invent: Life Sciences from TTP, we take a look at this fascinating new frontier for drug discovery.


Find out more on this week's episode of Invent: Life Sciences from TTP.


This Week's Guests

Dr. Sarah Morrow
Sarah is a Life Sciences Consultant at TTP, joining in 2020 after getting her PhD specialising in Organic Chemistry from the University of Oxford. Sarah brings a chemist’s perspective on the challenges encountered within drug discovery, as well as focusing on the technology - both hardware and software - that could enable and accelerate the field.
https://www.linkedin.com/in/sarah-morrow-841719146/

Aaron Morris
Aaron Morris is the CEO and co-founder of PostEra, a company building an end-to-end medicinal chemistry platform to advance drug discovery, using machine learning and AI to do so. After seeing the limiting nature of drug discovery on bio tech companies and pharma, Aaron set up PostEra to come in at this early stage and work alongside them to reduce these issues, and to serve the world's ever expanding community of drug hunters.
https://postera.ai/

Dr. Andreas Bender
Andreas Bender is a Professor of Life Sciences informatics interested in developing new life science data analysis methods for their application in drug discovery. After over a decade at Cambridge University working in molecular informatics, Andreas is now the CSO at Terra Lumina, a company building the world’s largest dataset of natural compounds, using AI that unlocks the connection between nature’s small molecules and the human body.
https://terralumina.bio/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 3 1 80a1abb2-c3c8-4855-8b3e-a38001aab787 <![CDATA[Synthetic Biology: How to change your genes]]> What is the potential of synthetic biology? A chance to create life-changing therapies by speaking cells’ very own language? Or could rogue researchers use it to turn our own biology against us?

Since synthetic biology emerged as a field, the aspirations for its benefits have been as speculative as the concerns about its misuse, making one of the most fascinating and divisive fields in life sciences. But what are its real applications today? And where is it going next? In this episode of Invent: Life Sciences we break down the history of this field, focusing in how breakthroughs in our understanding of DNA allowed it to flourish, before assessing whether its applications today will live up to its incredible potential.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Michael Chen
Michael is the CEO and founder of synthetic biology startup Nuclera. With a PHD in Chemistry from the University of Cambridge, Michael has ten years experience in scientific research, from nucleic acid chemistry to protein expression and crystallography, resulting in twelve published papers. Nuclera is the outcome of this work - it’s a company whose fundamental goal is to make biology accessible, through their groundbreaking desktop bioprinter, which combines eProtein synthesis and eDrop digital microfluidics, to enable protein printing within 24 hours.
https://www.nuclera.com/

Dr. Gary M. Skinner
Gary is a consultant in applied biophysics at TTP, and his research focuses on various fields within the syn bio space. In his career, Gary has worked everywhere from York to Arizona to the Netherlands on projects as far afield as using optical tweezers to observe initiation of transcription of DNA, to applying super-resolution imaging technology to DNA sequencing.
https://www.linkedin.com/in/gmskinnerbioscience/


Professor Tom Ellis

Tom is a Professor of Synthetic Genome Engineering at Imperial College London. He currently leads a research team in synthetic genome engineering and synthetic biology in the Department of Bioengineering. His research, for which he has one multiple awards, focuses on developing the foundational tools for accelerating, automating and scaling design-led synthetic genomics and synthetic biology.
https://www.linkedin.com/in/tomellisphd/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 07 Jun 2022 07:00:00 -0400 https://ttp.com/invent 44:50 What is the potential of synthetic biology? A chance to create life-changing therapies by speaking cells’ very own language? Or could rogue researchers use it to turn our own biology against us?

Since synthetic biology emerged as a field, the aspirations for its benefits have been as speculative as the concerns about its misuse, making one of the most fascinating and divisive fields in life sciences. But what are its real applications today? And where is it going next? In this episode of Invent: Life Sciences we break down the history of this field, focusing in how breakthroughs in our understanding of DNA allowed it to flourish, before assessing whether its applications today will live up to its incredible potential.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Michael Chen
Michael is the CEO and founder of synthetic biology startup Nuclera. With a PHD in Chemistry from the University of Cambridge, Michael has ten years experience in scientific research, from nucleic acid chemistry to protein expression and crystallography, resulting in twelve published papers. Nuclera is the outcome of this work - it’s a company whose fundamental goal is to make biology accessible, through their groundbreaking desktop bioprinter, which combines eProtein synthesis and eDrop digital microfluidics, to enable protein printing within 24 hours.
https://www.nuclera.com/

Dr. Gary M. Skinner
Gary is a consultant in applied biophysics at TTP, and his research focuses on various fields within the syn bio space. In his career, Gary has worked everywhere from York to Arizona to the Netherlands on projects as far afield as using optical tweezers to observe initiation of transcription of DNA, to applying super-resolution imaging technology to DNA sequencing.
https://www.linkedin.com/in/gmskinnerbioscience/


Professor Tom Ellis

Tom is a Professor of Synthetic Genome Engineering at Imperial College London. He currently leads a research team in synthetic genome engineering and synthetic biology in the Department of Bioengineering. His research, for which he has one multiple awards, focuses on developing the foundational tools for accelerating, automating and scaling design-led synthetic genomics and synthetic biology.
https://www.linkedin.com/in/tomellisphd/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> What is the potential of synthetic biology? A chance to create life-changing therapies by speaking cells’ very own language? Or could rogue researchers use it to turn our own biology against us?

Since synthetic biology emerged as a field, the aspirations for its benefits have been as speculative as the concerns about its misuse, making one of the most fascinating and divisive fields in life sciences. But what are its real applications today? And where is it going next? In this episode of Invent: Life Sciences we break down the history of this field, focusing in how breakthroughs in our understanding of DNA allowed it to flourish, before assessing whether its applications today will live up to its incredible potential.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Michael Chen
Michael is the CEO and founder of synthetic biology startup Nuclera. With a PHD in Chemistry from the University of Cambridge, Michael has ten years experience in scientific research, from nucleic acid chemistry to protein expression and crystallography, resulting in twelve published papers. Nuclera is the outcome of this work - it’s a company whose fundamental goal is to make biology accessible, through their groundbreaking desktop bioprinter, which combines eProtein synthesis and eDrop digital microfluidics, to enable protein printing within 24 hours.
https://www.nuclera.com/

Dr. Gary M. Skinner
Gary is a consultant in applied biophysics at TTP, and his research focuses on various fields within the syn bio space. In his career, Gary has worked everywhere from York to Arizona to the Netherlands on projects as far afield as using optical tweezers to observe initiation of transcription of DNA, to applying super-resolution imaging technology to DNA sequencing.
https://www.linkedin.com/in/gmskinnerbioscience/


Professor Tom Ellis

Tom is a Professor of Synthetic Genome Engineering at Imperial College London. He currently leads a research team in synthetic genome engineering and synthetic biology in the Department of Bioengineering. His research, for which he has one multiple awards, focuses on developing the foundational tools for accelerating, automating and scaling design-led synthetic genomics and synthetic biology.
https://www.linkedin.com/in/tomellisphd/


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 2 1 c4f02e09-4a4e-4a1e-8af8-0b152d4037b1 <![CDATA[Genomics: How to use a $100 genome]]> When the first human genome was sequenced, the whole project was estimated to have cost some 3 billion dollars and took over 13 years. Now, with massively parallel Next Generation Sequencing it is possible to sequence the human genome in less than 24 hours at a cost of under $1,000. With a rapid decline in sequencing costs, both the number of applications and the amount of data produced have boomed, driving a revolution in medicine. However, with the advent of new enabling technologies, what is next? What are the new and exciting technologies in the sequencing space which will be truly disruptive in the future? And what technical innovation is required to bring these technologies to the mainstream user or even the clinic?


In this episode of Invent: Life Sciences, we explore the race to innovate in the sequencing arena, what’s happened so far, and what’s going to happen next.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Geoff Smith
Geoff is a next generation sequencing pioneer who has built and led many of the teams that invented and developed the entire NGS workflow - from sample prep, to the core sequencing technology, to new instrument systems. Previously Ilumina's global head of ​​technology development, he is now an independent board member of various exciting start ups.
https://www.linkedin.com/in/geoff-smith-328b5b9/

Dr. Lauren Laing
Lauren leads the 'Omics Team at TTP – a team addressing current needs in DNA and RNA sequencing and also looking to develop tools for future multi- proteo- and other ‘omic workflows. Prior to this Lauren has worked in developing new sequencing technologies, novel chemistries, approaches to automating sample preparation, and research applying sequencing in single cell and epigenetic applications.
https://www.linkedin.com/in/epigenomicslvl/  

Dr. James Hadfield
James is the Senior Director of Oncology Translational Medicine at AstraZeneca and author of the CoreGenomics blog, enseqlopedia. A life-sciences researcher and senior operational manager with over 20 years’ experience in Genomics technologies, James is a thought leader in genomics with a broad network across academia and industry.
http://enseqlopedia.com/coregenomics


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> Tue, 31 May 2022 07:00:00 -0400 https://ttp.com/invent 46:00 When the first human genome was sequenced, the whole project was estimated to have cost some 3 billion dollars and took over 13 years. Now, with massively parallel Next Generation Sequencing it is possible to sequence the human genome in less than 24 hours at a cost of under $1,000. With a rapid decline in sequencing costs, both the number of applications and the amount of data produced have boomed, driving a revolution in medicine. However, with the advent of new enabling technologies, what is next? What are the new and exciting technologies in the sequencing space which will be truly disruptive in the future? And what technical innovation is required to bring these technologies to the mainstream user or even the clinic?


In this episode of Invent: Life Sciences, we explore the race to innovate in the sequencing arena, what’s happened so far, and what’s going to happen next.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Geoff Smith
Geoff is a next generation sequencing pioneer who has built and led many of the teams that invented and developed the entire NGS workflow - from sample prep, to the core sequencing technology, to new instrument systems. Previously Ilumina's global head of ​​technology development, he is now an independent board member of various exciting start ups.
https://www.linkedin.com/in/geoff-smith-328b5b9/

Dr. Lauren Laing
Lauren leads the 'Omics Team at TTP – a team addressing current needs in DNA and RNA sequencing and also looking to develop tools for future multi- proteo- and other ‘omic workflows. Prior to this Lauren has worked in developing new sequencing technologies, novel chemistries, approaches to automating sample preparation, and research applying sequencing in single cell and epigenetic applications.
https://www.linkedin.com/in/epigenomicslvl/  

Dr. James Hadfield
James is the Senior Director of Oncology Translational Medicine at AstraZeneca and author of the CoreGenomics blog, enseqlopedia. A life-sciences researcher and senior operational manager with over 20 years’ experience in Genomics technologies, James is a thought leader in genomics with a broad network across academia and industry.
http://enseqlopedia.com/coregenomics


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> When the first human genome was sequenced, the whole project was estimated to have cost some 3 billion dollars and took over 13 years. Now, with massively parallel Next Generation Sequencing it is possible to sequence the human genome in less than 24 hours at a cost of under $1,000. With a rapid decline in sequencing costs, both the number of applications and the amount of data produced have boomed, driving a revolution in medicine. However, with the advent of new enabling technologies, what is next? What are the new and exciting technologies in the sequencing space which will be truly disruptive in the future? And what technical innovation is required to bring these technologies to the mainstream user or even the clinic?


In this episode of Invent: Life Sciences, we explore the race to innovate in the sequencing arena, what’s happened so far, and what’s going to happen next.


Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Geoff Smith
Geoff is a next generation sequencing pioneer who has built and led many of the teams that invented and developed the entire NGS workflow - from sample prep, to the core sequencing technology, to new instrument systems. Previously Ilumina's global head of ​​technology development, he is now an independent board member of various exciting start ups.
https://www.linkedin.com/in/geoff-smith-328b5b9/

Dr. Lauren Laing
Lauren leads the 'Omics Team at TTP – a team addressing current needs in DNA and RNA sequencing and also looking to develop tools for future multi- proteo- and other ‘omic workflows. Prior to this Lauren has worked in developing new sequencing technologies, novel chemistries, approaches to automating sample preparation, and research applying sequencing in single cell and epigenetic applications.
https://www.linkedin.com/in/epigenomicslvl/  

Dr. James Hadfield
James is the Senior Director of Oncology Translational Medicine at AstraZeneca and author of the CoreGenomics blog, enseqlopedia. A life-sciences researcher and senior operational manager with over 20 years’ experience in Genomics technologies, James is a thought leader in genomics with a broad network across academia and industry.
http://enseqlopedia.com/coregenomics


The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

]]> false full 1 1 a09b8278-36c3-4cb4-b1f3-bd404f013fdb <![CDATA[Invent: Life Sciences from TTP - Trailer]]> Following our thrilling first series of Invent all about health technology, the team at TTP are back with a new series all about the Life Sciences, to explore the impact of biology and technology on the life sciences sector.

Life sciences are often referred to as the Fourth Industrial Revolution, deploying biology and technology in real-world applications to transform medicine, diagnostics, and ultimately our ability to engineer the building blocks of life itself. From delivering cures using cell therapies to harnessing the genetic code, from learning from the Theranos scandal to understanding disruption in drug discovery, Invent: Life Sciences will take a deep dive into the most exciting developments in the field.

The new series begins May 31st - see you then!

]]> Tue, 24 May 2022 08:29:15 -0400 https://ttp.com/invent 2:55 Following our thrilling first series of Invent all about health technology, the team at TTP are back with a new series all about the Life Sciences, to explore the impact of biology and technology on the life sciences sector.

Life sciences are often referred to as the Fourth Industrial Revolution, deploying biology and technology in real-world applications to transform medicine, diagnostics, and ultimately our ability to engineer the building blocks of life itself. From delivering cures using cell therapies to harnessing the genetic code, from learning from the Theranos scandal to understanding disruption in drug discovery, Invent: Life Sciences will take a deep dive into the most exciting developments in the field.

The new series begins May 31st - see you then!

]]> Following our thrilling first series of Invent all about health technology, the team at TTP are back with a new series all about the Life Sciences, to explore the impact of biology and technology on the life sciences sector.

Life sciences are often referred to as the Fourth Industrial Revolution, deploying biology and technology in real-world applications to transform medicine, diagnostics, and ultimately our ability to engineer the building blocks of life itself. From delivering cures using cell therapies to harnessing the genetic code, from learning from the Theranos scandal to understanding disruption in drug discovery, Invent: Life Sciences will take a deep dive into the most exciting developments in the field.

The new series begins May 31st - see you then!

]]> false trailer 1